Hudson Bay Capital Management
BIO icon

Hudson Bay Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hudson Bay Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,000
Closed -$7.73M – 601
2020
Q3 		$7.73M Buy
+15,000
New +$7.6M 0.12% 150
2019
Q4 		– Sell
-34,625
Closed -$11.5M – 431
2019
Q3 		$11.5M Sell
34,625
-33,375
-49% -$10.9M 0.32% 59
2019
Q2 		$21.3M Buy
68,000
+27,822
+69% +$8.33M 0.49% 34
2019
Q1 		$12.3M Buy
40,178
+14,998
+60% +$4.05M 0.16% 125
2018
Q4 		$5.85M Buy
25,180
+2,546
+11% +$683K 0.08% 243
2018
Q3 		$7.08M Sell
22,634
-20,134
-47% -$6.25M 0.09% 209
2018
Q2 		$12.3M Sell
42,768
-27,726
-39% -$7.66M 0.17% 110
2018
Q1 		$17.6M Buy
+70,494
New +$17.9M 0.37% 42

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Hudson Bay Capital Management's BIO Position: Q4 2020 in Review

Hudson Bay Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2020, closing a stake of 15,000 shares — an estimated $7.73M sold.

Hudson Bay Capital Management first reported a position in BIO in Q1 2018 and held it in 8 quarters. The position peaked at $21.3M in Q2 2019. 490 funds tracked by Wall St. Rank hold BIO as of Q4 2020.

  • Hudson Bay Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2020 after selling out during the quarter.
  • Hudson Bay Capital Management sold 15,000 Bio-Rad Laboratories Class A shares in Q4 2020, an estimated $7.73M.
  • Hudson Bay Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2018 and held it in 8 quarters.
  • Hudson Bay Capital Management's Bio-Rad Laboratories Class A position peaked at $21.3M in Q2 2019.
  • 490 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2020.

Based on Hudson Bay Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.